. 2017 May 31;7:108. doi: 10.1186/s13568-017-0363-8

Table 2.

In vitro antifungal activity of the surfactin and rhamnolipid biosurfactant extracts (1.00 mg mL⁻¹) against a panel of clinical and environmental fungal isolates as determined by agar disc diffusion method

Organism	Antifungal zone diameter (mm)
Organism	Surfactin extract (0.26 ± 0.09 mg mL⁻¹)	Rhamnolipid extract (1.12 ± 0.08 mg mL⁻¹)
^a Cryptococcus neoformans CAB1063	Inactive	13 ± 0.8
^a Cryptococcus neoformans CAB1067	11.7 ± 0.5	14.3 ± 3.3
^a Cryptococcus neoformans CAB1055	15.3 ± 0.5	11.3 ± 0.9
^a Candida albicans 8911	13.3 ± 0.5	14.7 ± 0.5
^a Candida albicans 8912	13.3 ± 0.5	11.7 ± 0.5
^b Cryptococcus neoformans CAB1034	Inactive	18.3 ± 0.8
^b Cryptococcus neoformans CAB831	11.7 ± 1.7	15.3 ± 1.9
^b Cryptococcus neoformans CAB842	12.3 ± 0.9	Inactive
^b Cryptococcus neoformans CAB844	15.3 ± 1.2	16.7 ± 1.7
^b Candida albicans 1085	Inactive	14 ± 0.8

The surfactin and rhamnolipid extracts were observed to be at 32.8 and 34.4% purity, respectively

^a Clinical strain

^b Environmental strain